DGAP-Adhoc: Allianz SE: Leadership change at Allianz

New Post Public Reply Private Reply Replies (0) Message Board

News Desk 2018

Apr 24, 2015 at 2:00 PM

DGAP-Adhoc: Allianz SE: Leadership change at Allianz Deutschland

Allianz SE / Key word(s): Change of Personnel 24.04.2015 19:42 Dissemination of an Ad hoc announcement according to Â§ 15 WpHG, transmitted by DGAP - a service of EQS Group AG. The issuer is solely responsible for the content of this announcement. --------------------------------------------------------------------------- In its today's meeting the Supervisory Board of Allianz Deutschland AG, a 100% subsidiary of Allianz SE, appointed Dr. Manfred Knof (49) as Chairman of the Board of Management (CEO) and successor to Dr. Markus RieÃ (49) with immediate effect, subject to the usual fit & proper review of the Regulator. Manfred Knof joined Allianz Group in 1995. From 2006 - 2011 he acted as CEO of Allianz Suisse and thereafter became a Member of the Board of Management of Allianz Deutschland AG, responsible for Operations and Claims. In April 2014 he became Head of the Business Division Central and Eastern Europe of Allianz SE. Markus RieÃ was one of the top candidates for the position of Chairman of the Board of Management of Allianz SE, which will be assumed by Oliver BÃ¤te on May 7, 2015. By mutual consent and upon his request, Markus RieÃ resigns from the Board of Management of Allianz Deutschland AG. Markus RieÃ wishes to pursue new career challenges. Munich, April 24, 2015 --------------------------------------------------------------------------- Information and Explaination of the Issuer to this News: As always, the evaluations are subject to the following cautionary notes. Cautionary Note Regarding Forward-Looking Statements The statements contained herein may include prospects, statements of future expectations and other forward-looking statements that are based on management's current views and assumptions and involve known and unknown risks and uncertainties. Actual results, performance or events may differ materially from those expressed or implied in such forward-looking statements. Such deviations may arise due to, without limitation, (i) changes of the general economic conditions and competitive situation, particularly in the Allianz Group's core business and core markets, (ii) performance of financial markets (particularly market volatility, liquidity and credit events), (iii) frequency and severity of insured loss events, including from natural catastrophes, and the development of loss expenses, (iv) mortality and morbidity levels and trends, (v) persistency levels, (vi) particularly in the banking business, the extent of credit defaults, (vii) interest rate levels, (viii) currency exchange rates including the euro/US-dollar exchange rate, (ix) changes in laws and regulations, including tax regulations, (x) the impact of acquisitions, including related integration issues, and reorganization measures, and (xi) general competitive factors, in each case on a local, regional, national and/or global basis. Many of these factors may be more likely to occur, or more pronounced, as a result of terrorist activities and their consequences. No duty to update The company assumes no obligation to update any information or forward-looking statement contained herein, save for any information required to be disclosed by law. 24.04.2015 The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Media archive at www.dgap-medientreff.de and www.dgap.de --------------------------------------------------------------------------- Language: English Company: Allianz SE KÃ¶niginstr. 28 80802 MÃ¼nchen Germany Phone: +49 (0)89 38 00 - 41 24 Fax: +49 (0)89 38 00 - 38 99 E-mail: investor.relations@allianz.com Internet: www.allianz.com ISIN: DE0008404005 WKN: 840400 Indices: DAX-30, EURO STOXX 50 Listed: Regulated Market in Berlin, Dusseldorf, Frankfurt (Prime Standard), Hamburg, Hanover, Munich, Stuttgart; TerminbÃ¶rse EUREX End of Announcement DGAP News-Service ---------------------------------------------------------------------------

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Aluminum Design Fumble: Geometry Over Wall Thickness

A Misstep in Aluminum Design Practices Well, here's a nugget of wisdom for the metal enthusiasts out there—stop beefing up aluminum components with thicker walls and focus on smart geometry. This isn't a drill, folks. Mark Coyle, a seasoned mind over at American Custom Metals, has been waving the flag for smarter aluminum design methods right from Rochester, NY, and...

Bio-Thera's New Data: A Game Changer for NSCLC?

A Fresh Look at Lung Cancer Solutions There's fresh meat on the oncology block, with Bio-Thera Solutions swinging for the fences at ESMO 2026, spotlighting promising Phase 2 clinical data for their combo treatment in first-line non-small cell lung cancer (NSCLC). If you're tuned into the biopharmaceutical sector or just keeping tabs on global health romps, this news sets...

World Young Scientist Summit 2026 in Wenzhou Kicks Off

Young Minds Meet AI Innovation Crack open the playbook, and it's clear: young brains from across the globe are gathering in Wenzhou, Zhejiang, China, to wrangle with AI and chart the course of science toward a sustainable future. The World Young Scientist Summit 2026 isn't just a parade of speeches and accolades. Nah, it's a deep dive into where innovative minds believe...

ST Engineering iDirect, MBSat Forge Middle East Satellite Hub

Satellite Services Take Off in the Middle East Never thought the day would come where the Middle East is on the threshold of leapfrogging satellite tech, but here we are. ST Engineering iDirect just locked arms with MBSat—yep, that's part of the Mohammed Al Barwani Group—to birth a next-gen satellite connectivity service hub in Oman and across surrounding areas....

Taiwan Fuses Ancient TCM with Modern Bio Tech in 2026

The Dynamic Fusion of Heritage and Innovation When you think about it, mixing centuries-old herbal wisdom with today's cutting-edge biotech might sound like a plot twist, but that's exactly what's cooking in Taiwan. Over at SupplySide Global 2026 in Las Vegas, Taiwan's got something more than just traditional medicine to flaunt; it's showcasing an impressive fusion of...

Spooky Dining at CARNE: A Halloween Hit in Oxnard

A Festive Transformation at CARNE Rolling into Oxnard, you're met with an unconventional dining spectacle at CARNE. It's not your average restaurant fare as they've pulled out the stops with their spirited Halloween pop-up, A Nightmare at CARNE. Channeling the eerie charm of "The Nightmare Before Christmas," this temporary transformation morphs the venue into a lively,...

Swanson Nexus Pro Launch: Boost for Dietitians

By Lucas Young Updated Oct 24, 2026 Category News Views 184

Swanson Enters the Education Arena for Nutritionists Swanson Vitamins is mixing things up again! This time, they're launching something called Swanson Vitamins Nexus Pro, aimed squarely at the registered dietitians and licensed nutritionists crowd. Starting out as the place to grab your basic vitamins, Swanson's not resting on their supplement laurels. No, siree. They've...

Axon Body 5: A Leap Forward in AI for Public Safety

Axon Raises the Stakes with Body 5 Camera Boy, oh boy, Axon's dropped a bombshell with the Body 5. We're talking a colossal leap into the AI era for public safety, and if you're in the biz, you can't just shrug this one off. We're looking at 25 times the AI processing power compared to Axon's old units. That's right, I said twenty-five. Real-time situational awareness in...

Amgen's IMDELLTRA® Shows Promise in SCLC Battle

Breakthrough Results in SCLC Treatment For years, small cell lung cancer (SCLC) has been the unruly beast in the oncology world, defying treatment advances and keeping survival rates stubbornly low. This nasty foe might just have met its match, folks. Amgen (NASDAQ:AMGN) announced results from their Phase 3 DeLLphi-305 trial that show their drug IMDELLTRA®, when teamed...

Wenda Pharma's NHWD-870 HCl Shows Promise in Trial

Breaking Through in NUT Carcinoma Treatment Imagine battling an aggressive disease with barely any options left, and then something hopeful shows up in the pipeline. That's the story with Zhejiang Wenda Pharma's NHWD-870 HCl, an oral BET inhibitor making waves at the 2026 ESMO Annual Meeting. Facing off against the nasty beast that is NUT carcinoma, this drug didn't just...